Pharma Equity Group A/S

PEG A

DK0061155009

Investment Holding Companies

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 05/07/2024 pm IST			5-day change	1st Jan Change
0.252 ^DKK	-14.29%		-14.86%	-41.40%

17/05	Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/05	Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	CI

Blue Vision A/S : 207_Financial Calendar 2016_06-01-2016_nr.1.pdf

January 07, 2016 at 02:16 am IST

bcfad717-1747-46c0-ad87-001aa0105a1f.pdf

Date: 6. January 2016 Company announcement no.: 1

Page 1 of 1.

BLUE VISION A/S - Finance schedule for 2016

Please find below the finance schedule for 2016.

31. March 2016 Public announcement of the Annual report for 2015

15. April 2016 Public announcement of the Interim report for the 1st. quarter 2016

29. April 2016 Ordinary general meeting for 2015

15. July 2016 Public announcement of the Interim report for the 2nd. quarter 2016

14. October 2016 Public announcement of the Interim report for the 3rd. quarter 2016

31. March 2017 Public announcement of the Annual report for 2016

28. April 2017 Ordinary general meeting for 2016

Best regards. Blue Vision A/S

Leif Erlandsen Chairman

Blue Vision A/S Philip Heymans Allé 3, 1 DK-2900 Hellerup

Blue Vision A/S issued this content on 2016-01-06 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-06 20:45:03 UTC

Original Document: http://www.blue-vision.dk/images/FInanskalender/Finanskalender2016Engelsk.pdf

Latest news about Pharma Equity Group A/S

Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05	CI
Pharma Equity Group A/S Maintains Group Earnings Guidance for the Full Year of 2024	16/05	CI
Pharma Equity Group A/S announced that it expects to receive DKK 1 million in funding	16/05	CI
Pharma Equity Group A/S announced that it has received DKK 7.6 million in funding	10/04	CI
Pharma Equity Group?s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company?s patented drug candidate RNX-051	05/04	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Pharma Equity Group A/S Provides Group Earnings Guidance for the Full Year 2024	20/03	CI
Pharma Equity Group A/S announced that it expects to receive DKK 7.1 million in funding	07/02	CI
Pharma Equity Group A/S announced that it has received DKK 8.914795 million in funding	25/01	CI
Pharma Equity Group's Subsidiary (Reponex Pharmaceuticals A/S) Receives Notification from the European Patent Office	22/01	CI
Pharma Equity Group A/S announced that it expects to receive DKK 8.914795 million in funding	22/01	CI
Pharma Equity Group A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	18/01	CI
Pharma Equity Group Unit Meets Primary Endpoints in Colon Cancer Treatment Trial	16/11	MT
Pharma Equity Group A/S Announces Positive Preliminary Results from the Phase-2 Clinical Trial	16/11	CI
Pharma Equity Group A/S Approves Board Appointments	02/11	CI
Pharma Equity Group?S Subsidiary Company Reponex Pharmaceuticals A/S Receives Grant of Us Patent for A Method of Treatment on Its Topical Wound-Healing Composition	31/23/31	CI
Pharma Equity Group A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/23/16	CI
Reponex Pharmaceuticals Set for US Patent for Chronic Wound Treatment Method	15/23/15	MT
Pharma Equity Group A/S Announces Board Changes	15/23/15	CI
Reponex Pharmaceuticals A/S Announces CEO Changes	14/23/14	CI
Reponex Pharmaceuticals A/S Names Dr Christopher M Burton MD, PhD as Chief Medical Officer	14/23/14	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Pharma Equity Group A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Pharma Equity Group A/S Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Reponex Pharmaceuticals A/S completed the acquisition of Pharma Equity Group A/S.	24/23/24	CI

Pharma Equity Group A/S, formerly Blue Vision A/S, is a Denmark-based company. The Company's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to be the biopharmaceutical company that develops the local treatments for serious, acute and chronic inflammatory diseases. The Company's purpose is also to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.

Sector

Investment Holding Companies

Calendar

16/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Holding Companies

	1st Jan change	Capi.
PHARMA EQUITY GROUP A/S	-41.40%	37.42M
INVESTOR AB	+24.10%	84.25B
KOÇ HOLDING	+61.85%	17.81B
INVESTMENT AB LATOUR	+11.67%	17.86B
AB INDUSTRIVÄRDEN	+7.94%	14.57B
BAJAJ HOLDINGS & INVESTMENT LIMITED	+25.65%	12.85B
L E LUNDBERGFÖRETAGEN AB	-2.86%	12.6B
MERITZ FINANCIAL GROUP INC.	+41.12%	11.13B
HAL TRUST	-1.05%	11.01B
GROUPE BRUXELLES LAMBERT SA	-3.89%	9.57B